Inhibition of proteasome function induced apoptosis in gastric cancer

The ubiquitin‐proteasome pathway plays a critical role in the degradation of cellular proteins and cell cycle control. Dysregulating the degradation of such proteins should have profound effects on tumor growth and causes cells to undergo apoptosis. The aims of this study are to evaluate the ubiquitin‐proteasome pathway in gastric cancer and the potential role of pharmacological inhibition of proteasome on induction of apoptosis in gastric cancer cells. Gastric cancer cell lines AGS (p53 wild‐type) and MKN‐28 (p53 mutant) were treated with proteasome inhibitor MG132. The results showed that MG132 inhibited cell proliferation in AGS and MKN‐28 cells in a time‐ and dose‐dependent manner. The inhibition of cell proliferation was caused by apoptosis which was also time‐ and dose‐dependent. AGS cells were more responsive to MG132 than MKN‐28 cells. Induction of apoptosis was preceded by the activation of caspase‐3, as measured by a colorimetric caspase‐3 cellular activity and Western blotting of the cleavage of caspase‐3 and its substrate PARP. Activation of caspase‐7 was also exhibited. In addition, z‐VAD‐fmk, a broad spectrum caspase inhibitor, reversed apoptosis induced by MG132 in AGS and MKN28 cells. Although z‐DEVD‐fmk, a specific caspase‐3 inhibitor, suppressed MG132‐induced apoptosis in MKN28 cells, it only partially rescued the apoptotic effect in AGS cells. Caspase‐3 activation was the result of release of cytochrome c from mitochondria into the cytosol, as a consequence of upregulation of bax. There were overexpressions of all the proteasome‐related proteins p53, p21waf1 and p27kip1 at 4 hr after proteasome inhibition which was identified by the accumulation of ubiquitin‐tagged proteins. This was accompanied by accumulation of cells at G1 phase. Our present study suggests that inhibition of proteasome function in gastric cancer cells induces apoptosis and proteasomal inhibitors have potential use as novel anticancer drugs in gastric cancer. © 2001 Wiley‐Liss, Inc.

[1]  G. Salvesen,et al.  Cleavage of Automodified Poly(ADP-ribose) Polymerase during Apoptosis , 1999, The Journal of Biological Chemistry.

[2]  D. Green,et al.  Mitochondrial cytochrome c release in apoptosis occurs upstream of DEVD‐specific caspase activation and independently of mitochondrial transmembrane depolarization , 1998, The EMBO journal.

[3]  John Calvin Reed.  Bcl-2 and the regulation of programmed cell death , 1994, The Journal of cell biology.

[4]  S. Ōmura,et al.  Proteasome inhibitors induce mitochondria‐independent apoptosis in human glioma cells , 1999, FEBS letters.

[5]  P. Beer-Romero,et al.  Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. , 1995, Science.

[6]  M. Sherman,et al.  Proteasome Inhibitors Activate Stress Kinases and Induce Hsp72 , 1998, The Journal of Biological Chemistry.

[7]  O. Halevy,et al.  Conditional inhibition of transformation and of cell proliferation by a temperature-sensitive mutant of p53 , 1990, Cell.

[8]  P. Seth,et al.  Promoting apoptosis: a novel activity associated with the cyclin-dependent kinase inhibitor p27. , 1997, Cancer research.

[9]  U. Lopes,et al.  p53-dependent Induction of Apoptosis by Proteasome Inhibitors* , 1997, The Journal of Biological Chemistry.

[10]  S. Korsmeyer.  Regulators of cell death. , 1995, Trends in genetics : TIG.

[11]  M L Agarwal,et al.  The p53 Network* , 1998, The Journal of Biological Chemistry.

[12]  B. Vogelstein,et al.  Participation of p53 protein in the cellular response to DNA damage. , 1991, Cancer research.

[13]  S. Christakos,et al.  Apoptosis and signal transduction: clues to a molecular mechanism. , 1993, Current opinion in cell biology.

[14]  Yi-Song Wang,et al.  WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. , 1994, Cancer research.

[15]  Q. Dou,et al.  Novel dipeptidyl proteasome inhibitors overcome Bcl-2 protective function and selectively accumulate the cyclin-dependent kinase inhibitor p27 and induce apoptosis in transformed, but not normal, human fibroblasts , 1998, Cell Death and Differentiation.

[16]  Z. Su,et al.  Induction of differentiation in human promyelocytic HL-60 leukemia cells activates p21, WAF1/CIP1, expression in the absence of p53. , 1994, Oncogene.

[17]  S. Ōmura,et al.  mdm2 and bax, downstream mediators of the p53 response, are degraded by the ubiquitin-proteasome pathway. , 1998, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[18]  A. Ciechanover,et al.  The ubiquitin-proteasome pathway: the complexity and myriad functions of proteins death. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[19]  S. Hirohashi,et al.  p53 Mutation in gastric cancer: A genetic model for carcinogenesis is common to gastric and colorectal cancer , 1993, International journal of cancer.

[20]  D. Green,et al.  Bax-induced Caspase Activation and Apoptosis via Cytochromec Release from Mitochondria Is Inhibitable by Bcl-xL* , 1999, The Journal of Biological Chemistry.

[21]  H. Drexler.  Activation of the cell death program by inhibition of proteasome function. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[22]  K Weber,et al.  Intermediate filaments: structure, dynamics, function, and disease. , 1994, Annual review of biochemistry.

[23]  S. Ōmura,et al.  Proteasome-dependent regulation of p21WAF1/CIP1 expression. , 1996, Biochemical and biophysical research communications.

[24]  P. Howley,et al.  In vivo ubiquitination and proteasome-mediated degradation of p53(1). , 1996, Cancer research.

[25]  K Tanaka,et al.  Structure and functions of the 20S and 26S proteasomes. , 1996, Annual review of biochemistry.

[26]  A. Goldberg,et al.  Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules , 1994, Cell.

[27]  J C Reed,et al.  Bax directly induces release of cytochrome c from isolated mitochondria. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[28]  N. Thornberry,et al.  Caspases: killer proteases. , 1997, Trends in biochemical sciences.

[29]  C. Caskey,et al.  Biochemical characterization of azetidine carboxylic acid-resistant Chinese hamster cells , 1976, Cell.

[30]  A. Hershko.  Roles of ubiquitin-mediated proteolysis in cell cycle control. , 1997, Current opinion in cell biology.

[31]  Shai Shaham,et al.  The C. elegans cell death gene ced-3 encodes a protein similar to mammalian interleukin-1β-converting enzyme , 1993, Cell.

[32]  R. Orlowski.  The role of the ubiquitin-proteasome pathway in apoptosis , 1999, Cell Death and Differentiation.

[33]  E. Sausville,et al.  Proteasome inhibitors: a novel class of potent and effective antitumor agents. , 1999, Cancer research.

[34]  J. Mankovich,et al.  Substrate Specificities of Caspase Family Proteases* , 1997, The Journal of Biological Chemistry.

[35]  S. Ōmura,et al.  Proteasome regulation of activation-induced T cell death. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[36]  Xiaodong Wang,et al.  Induction of Apoptotic Program in Cell-Free Extracts: Requirement for dATP and Cytochrome c , 1996, Cell.

[37]  K. Shinohara,et al.  Apoptosis induction resulting from proteasome inhibition. , 1996, The Biochemical journal.

[38]  Junying Yuan,et al.  Human ICE/CED-3 Protease Nomenclature , 1996, Cell.

[39]  M. Grever,et al.  Tumor growth inhibition induced in a murine model of human Burkitt's lymphoma by a proteasome inhibitor. , 1998, Cancer research.

[40]  Z. Darżynkiewicz,et al.  Features of apoptotic cells measured by flow cytometry. , 1992, Cytometry.

[41]  David L. Vaux,et al.  An evolutionary perspective on apoptosis , 1994, Cell.

[42]  Howard Hughes.  Lactacystin, Proteasome Function, and Cell Fate* , 1998, The Journal of Biological Chemistry.

[43]  S Omura,et al.  The proteasome is involved in angiogenesis. , 1998, Biochemical and biophysical research communications.